{"id":16827,"date":"2026-03-10T04:55:08","date_gmt":"2026-03-10T04:55:08","guid":{"rendered":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/?p=16827"},"modified":"2026-03-10T05:52:29","modified_gmt":"2026-03-10T05:52:29","slug":"gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024","status":"publish","type":"post","link":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/","title":{"rendered":"When Drug Names Sound Alike: Why the Delhi High Court Cancelled \u2018OTRINIR\u2019 to Protect Patients"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\" id=\"gsk-consumer-healthcare-vs-celebrity-biopharma-2024\"><span class=\"ez-toc-section\" id=\"Gsk_Consumer_Healthcare_SA_vs_Celebrity_Biopharma_Ltd_Anr_2024_A_Landmark_Decision_on_Pharmaceutical_Trademark_Similarity\"><\/span>Gsk Consumer Healthcare S.A. vs. Celebrity Biopharma Ltd. &amp; Anr. (2024): A Landmark Decision on Pharmaceutical Trademark Similarity<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><th>Particulars<\/th><th>Details<\/th><\/tr><tr><td><strong>Court<\/strong><\/td><td>Delhi High Court<\/td><\/tr><tr><td><strong>Date Of Judgment<\/strong><\/td><td>22 March 2024<\/td><\/tr><tr><td><strong>Statute<\/strong><\/td><td>Trade Marks Act, 1999 \u2013 Sections 57, 9, and 11<\/td><\/tr><tr><td><strong>Nature Of Case<\/strong><\/td><td>Trademark Rectification \/ Cancellation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"introduction\"><span class=\"ez-toc-section\" id=\"Introduction\"><\/span>Introduction<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Trademark law performs a dual function. It protects the commercial goodwill of businesses while simultaneously safeguarding consumers from confusion in the marketplace. These objectives assume heightened importance in the pharmaceutical sector, where confusion between two similar medicines can potentially endanger public health.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #0c0c0c;color:#0c0c0c\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #0c0c0c;color:#0c0c0c\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#Gsk_Consumer_Healthcare_SA_vs_Celebrity_Biopharma_Ltd_Anr_2024_A_Landmark_Decision_on_Pharmaceutical_Trademark_Similarity\" >Gsk Consumer Healthcare S.A. vs. Celebrity Biopharma Ltd. &amp; Anr. (2024): A Landmark Decision on Pharmaceutical Trademark Similarity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#Introduction\" >Introduction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#1_Background_Of_The_Dispute\" >1. Background Of The Dispute<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#Timeline_Of_Events\" >Timeline Of Events<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#2_Legal_Framework\" >2. Legal Framework<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#Section_57_%E2%80%93_Rectification_And_Cancellation\" >Section 57 \u2013 Rectification And Cancellation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#Section_9_%E2%80%93_Absolute_Grounds_For_Refusal\" >Section 9 \u2013 Absolute Grounds For Refusal<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#Section_11_%E2%80%93_Relative_Grounds_For_Refusal\" >Section 11 \u2013 Relative Grounds For Refusal<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#3_Central_Legal_Issue\" >3. Central Legal Issue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#4_Arguments_Presented_By_GSK_Petitioner\" >4. Arguments Presented By GSK (Petitioner)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#a_Prior_Use_And_Global_Reputation\" >(a) Prior Use And Global Reputation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#b_Deceptive_Similarity\" >(b) Deceptive Similarity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#c_Identical_Goods\" >(c) Identical Goods<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#d_Dishonest_Adoption\" >(d) Dishonest Adoption<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#e_Violation_Of_Statutory_Provisions\" >(e) Violation Of Statutory Provisions<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#5_Respondents_Arguments\" >5. Respondent\u2019s Arguments<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#a_%E2%80%9COTRI%E2%80%9D_Is_Generic\" >(a) \u201cOTRI\u201d Is Generic<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#b_Distinct_Suffix\" >(b) Distinct Suffix<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#c_Anti-Dissection_Rule\" >(c) Anti-Dissection Rule<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#6_The_Courts_Analysis\" >6. The Court\u2019s Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#1_Phonetic_Similarity\" >(1) Phonetic Similarity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#2_Structural_Similarity\" >(2) Structural Similarity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#3_Visual_Similarity\" >(3) Visual Similarity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#4_Nature_Of_Goods\" >(4) Nature Of Goods<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#5_Prior_Use_And_Reputation\" >(5) Prior Use And Reputation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#6_Generic_Argument_Rejected\" >(6) Generic Argument Rejected<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#7_The_Judgment\" >7. The Judgment<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#Key_Findings\" >Key Findings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#Courts_Directions\" >Court\u2019s Directions<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#8_Legal_Principles_Reinforced_by_the_Judgment\" >8. Legal Principles Reinforced by the Judgment<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#1_Prior_User_Prevails\" >1. Prior User Prevails<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#2_Deceptive_Similarity_Test\" >2. Deceptive Similarity Test<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#3_Higher_Standard_for_Pharmaceutical_Trademarks\" >3. Higher Standard for Pharmaceutical Trademarks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#4_Prefix_Dominance_Rule\" >4. Prefix Dominance Rule<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#5_Public_Interest_in_Trademark_Law\" >5. Public Interest in Trademark Law<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#9_Practical_Lessons_for_Businesses_and_Lawyers\" >9. Practical Lessons for Businesses and Lawyers<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#For_Pharmaceutical_Companies\" >For Pharmaceutical Companies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#For_Trademark_Lawyers\" >For Trademark Lawyers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#For_Trademark_Registry\" >For Trademark Registry<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#10_Broader_Impact_of_the_Decision\" >10. Broader Impact of the Decision<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#Conclusion\" >Conclusion<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court-2024\/#Take_Action_Protect_Your_Copyright_the_Right_Way\" >Take Action: Protect Your Copyright the Right Way<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n\n\n\n<p>The decision of the Delhi High Court in GSK Consumer Healthcare S.A. v. Celebrity Biopharma Ltd. &amp; Anr. (2024) illustrates how Indian courts apply the principles of deceptive similarity and prior user rights in pharmaceutical trademarks.<\/p>\n\n\n\n<p>The Court examined whether the mark \u201cOTRINIR\u201d could coexist with the well-known nasal decongestant brand \u201cOTRIVIN\u201d, and ultimately ordered cancellation of the later mark from the trademark register.<\/p>\n\n\n\n<p>The judgment reinforces the judiciary\u2019s consistent approach that even minor similarities between pharmaceutical trademarks may be unacceptable, particularly where the earlier mark enjoys longstanding reputation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"background-of-the-dispute\"><span class=\"ez-toc-section\" id=\"1_Background_Of_The_Dispute\"><\/span>1. Background Of The Dispute<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The petitioner, GSK Consumer Healthcare S.A., forms part of the global GlaxoSmithKline group, a multinational pharmaceutical and healthcare corporation. The company owns the trademark \u201cOTRIVIN\u201d, widely used for nasal decongestant sprays.<\/p>\n\n\n\n<p>The OTRIVIN brand has existed in the market since around 1950, and over decades it has acquired substantial reputation and goodwill among doctors, pharmacists, and consumers.<\/p>\n\n\n\n<p>The dispute arose when Celebrity Biopharma Ltd., the respondent, obtained registration of the mark \u201cOTRINIR\u201d in Class 5 under the Trade Marks Act, covering pharmaceutical preparations, including nasal sprays.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"timeline-of-events\"><span class=\"ez-toc-section\" id=\"Timeline_Of_Events\"><\/span>Timeline Of Events<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><th>Year \/ Date<\/th><th>Event<\/th><\/tr><tr><td>1950s<\/td><td>OTRIVIN introduced internationally as a nasal decongestant.<\/td><\/tr><tr><td>Subsequent decades<\/td><td>Extensive sales and reputation established.<\/td><\/tr><tr><td>2013<\/td><td>Celebrity Biopharma adopts and registers OTRINIR.<\/td><\/tr><tr><td>April 2020<\/td><td>GSK becomes aware of the registration.<\/td><\/tr><tr><td>1 August 2020<\/td><td>GSK sends a legal notice demanding cessation of use.<\/td><\/tr><tr><td>Respondent refuses<\/td><td>Leading to litigation.<\/td><\/tr><tr><td>Rectification petition filed<\/td><td>Filed under Section 57 of the Trade Marks Act before the Delhi High Court.<\/td><\/tr><tr><td>22 March 2024<\/td><td>Court delivers judgment.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"legal-framework\"><span class=\"ez-toc-section\" id=\"2_Legal_Framework\"><\/span>2. Legal Framework<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The dispute involved key provisions of the Trade Marks Act, 1999.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"section-57-rectification-and-cancellation\"><span class=\"ez-toc-section\" id=\"Section_57_%E2%80%93_Rectification_And_Cancellation\"><\/span>Section 57 \u2013 Rectification And Cancellation<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Section 57 allows any aggrieved person to apply for removal or cancellation of a trademark from the register if the registration:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>was wrongly made; or<\/li>\n\n\n\n<li>remains wrongly on the register.<\/li>\n<\/ul>\n\n\n\n<p>Rectification petitions are often used when a mark is registered despite conflicting with an earlier trademark.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"section-9-absolute-grounds-for-refusal\"><span class=\"ez-toc-section\" id=\"Section_9_%E2%80%93_Absolute_Grounds_For_Refusal\"><\/span>Section 9 \u2013 Absolute Grounds For Refusal<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Section 9 prohibits registration of marks that are likely to deceive or cause confusion.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"section-11-relative-grounds-for-refusal\"><span class=\"ez-toc-section\" id=\"Section_11_%E2%80%93_Relative_Grounds_For_Refusal\"><\/span>Section 11 \u2013 Relative Grounds For Refusal<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Section 11 bars registration of a trademark if:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>it is identical or similar to an earlier mark, and<\/li>\n\n\n\n<li>the goods\/services are identical or similar, creating a likelihood of confusion.<\/li>\n<\/ul>\n\n\n\n<p>Together, these provisions ensure that later trademarks do not encroach upon established brand rights.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Provision<\/th><th>Purpose Under The Trade Marks Act, 1999<\/th><\/tr><\/thead><tbody><tr><td>Section 57<\/td><td>Allows rectification or cancellation of wrongly registered trademarks.<\/td><\/tr><tr><td>Section 9<\/td><td>Prevents registration of deceptive or confusing trademarks.<\/td><\/tr><tr><td>Section 11<\/td><td>Protects earlier trademarks against similar later registrations.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"central-legal-issue\"><span class=\"ez-toc-section\" id=\"3_Central_Legal_Issue\"><\/span>3. Central Legal Issue<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The principal question before the Court was:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Whether the trademark \u201cOTRINIR\u201d is deceptively similar to GSK\u2019s earlier mark \u201cOTRIVIN\u201d, thereby creating a likelihood of confusion among consumers purchasing pharmaceutical products.<\/p>\n<\/blockquote>\n\n\n\n<p>The Court had to evaluate similarity from multiple perspectives, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>phonetic similarity<\/li>\n\n\n\n<li>visual resemblance<\/li>\n\n\n\n<li>structural composition<\/li>\n\n\n\n<li>nature of goods<\/li>\n\n\n\n<li>likelihood of confusion in the pharmaceutical market<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"arguments-by-gsk-petitioner\"><span class=\"ez-toc-section\" id=\"4_Arguments_Presented_By_GSK_Petitioner\"><\/span>4. Arguments Presented By GSK (Petitioner)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>GSK advanced several arguments to demonstrate that the impugned mark should be cancelled.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"prior-use-and-global-reputation\"><span class=\"ez-toc-section\" id=\"a_Prior_Use_And_Global_Reputation\"><\/span>(a) Prior Use And Global Reputation<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The company argued that OTRIVIN is a long-established pharmaceutical brand with global recognition.<\/p>\n\n\n\n<p>Decades of continuous use, extensive advertising, and significant sales had given the mark substantial goodwill in India and internationally.<\/p>\n\n\n\n<p>Under trademark law, the prior user principle ensures that earlier commercial use prevails over later adoption.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"deceptive-similarity\"><span class=\"ez-toc-section\" id=\"b_Deceptive_Similarity\"><\/span>(b) Deceptive Similarity<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>According to GSK:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Both marks begin with \u201cOTRI\u201d, the dominant portion.<\/li>\n\n\n\n<li>Consumers are likely to focus on the prefix rather than the suffix.<\/li>\n\n\n\n<li>When spoken, OTRIVIN and OTRINIR sound highly similar.<\/li>\n<\/ul>\n\n\n\n<p>This similarity was argued to create a real risk of consumer confusion, particularly in fast-paced retail environments such as pharmacies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"identical-goods\"><span class=\"ez-toc-section\" id=\"c_Identical_Goods\"><\/span>(c) Identical Goods<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Both marks were used for nasal decongestant sprays, falling within the same pharmaceutical category.<\/p>\n\n\n\n<p>Where goods are identical, courts apply a stricter test of similarity, because confusion becomes more likely.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"dishonest-adoption\"><span class=\"ez-toc-section\" id=\"d_Dishonest_Adoption\"><\/span>(d) Dishonest Adoption<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>GSK suggested that the respondent\u2019s choice of the mark was not coincidental.<\/p>\n\n\n\n<p>Given the long-standing presence of OTRIVIN in the pharmaceutical market, the respondent likely adopted OTRINIR to benefit from the reputation of the earlier brand.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"violation-of-statutory-provisions\"><span class=\"ez-toc-section\" id=\"e_Violation_Of_Statutory_Provisions\"><\/span>(e) Violation Of Statutory Provisions<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>GSK argued that the impugned registration violated:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Section 9(2)(a) \u2013 likelihood of deception<\/li>\n\n\n\n<li>Section 11 \u2013 conflict with earlier trademark rights<\/li>\n<\/ul>\n\n\n\n<p>Therefore, the registration should be removed from the trademark register.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"respondents-arguments\"><span class=\"ez-toc-section\" id=\"5_Respondents_Arguments\"><\/span>5. Respondent\u2019s Arguments<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Celebrity Biopharma resisted the rectification petition and raised several defenses.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"otri-is-generic\"><span class=\"ez-toc-section\" id=\"a_%E2%80%9COTRI%E2%80%9D_Is_Generic\"><\/span>(a) \u201cOTRI\u201d Is Generic<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The respondent claimed that the prefix \u201cOTRI\u201d is derived from otorhinolaryngology (ENT) and is therefore common in pharmaceutical nomenclature.<\/p>\n\n\n\n<p>If the prefix were considered generic or descriptive, it could not be monopolized by GSK.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"distinct-suffix\"><span class=\"ez-toc-section\" id=\"b_Distinct_Suffix\"><\/span>(b) Distinct Suffix<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Celebrity Biopharma argued that the suffix \u201cNIR\u201d sufficiently distinguishes the mark from \u201cVIN\u201d.<\/p>\n\n\n\n<p>Thus, the marks OTRINIR and OTRIVIN should be considered distinct.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"anti-dissection-rule\"><span class=\"ez-toc-section\" id=\"c_Anti-Dissection_Rule\"><\/span>(c) Anti-Dissection Rule<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The respondent relied on the anti-dissection principle, which states that trademarks must be evaluated as a whole, rather than dissected into individual components.<\/p>\n\n\n\n<p>In support, reliance was placed on the landmark Supreme Court decision in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd. (2001)<\/li>\n<\/ul>\n\n\n\n<p>In that case, the Court held that similarity must be judged from the perspective of an average consumer with imperfect recollection.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"courts-analysis\"><span class=\"ez-toc-section\" id=\"6_The_Courts_Analysis\"><\/span>6. The Court\u2019s Analysis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Delhi High Court undertook a detailed comparison of the competing marks.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"phonetic-similarity\"><span class=\"ez-toc-section\" id=\"1_Phonetic_Similarity\"><\/span>(1) Phonetic Similarity<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Both marks begin with \u201cOTRI\u201d, and when pronounced, the overall sound of OTRIVIN and OTRINIR is strikingly similar.<\/p>\n\n\n\n<p>Phonetic similarity carries particular importance in pharmaceutical products because:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>medicines are often ordered verbally, and<\/li>\n\n\n\n<li>prescriptions may be spoken or handwritten.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"structural-similarity\"><span class=\"ez-toc-section\" id=\"2_Structural_Similarity\"><\/span>(2) Structural Similarity<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The Court noted that:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>both marks consist of seven letters, and<\/li>\n\n\n\n<li>share the same initial structure.<\/li>\n<\/ul>\n\n\n\n<p>This structural resemblance increases the likelihood of confusion.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"visual-similarity\"><span class=\"ez-toc-section\" id=\"3_Visual_Similarity\"><\/span>(3) Visual Similarity<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Visually, the marks appear closely related.<\/p>\n\n\n\n<p>The shared prefix OTRI creates a dominant impression that overshadows the differing suffix.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"nature-of-goods\"><span class=\"ez-toc-section\" id=\"4_Nature_Of_Goods\"><\/span>(4) Nature Of Goods<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Both marks relate to nasal decongestant sprays.<\/p>\n\n\n\n<p>Where goods are identical, even small differences between marks may not prevent confusion.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"prior-use-and-reputation\"><span class=\"ez-toc-section\" id=\"5_Prior_Use_And_Reputation\"><\/span>(5) Prior Use And Reputation<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The Court placed significant weight on GSK\u2019s long-standing use of OTRIVIN.<\/p>\n\n\n\n<p>The respondent\u2019s adoption in 2013 came decades after the establishment of the earlier brand.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"generic-argument-rejected\"><span class=\"ez-toc-section\" id=\"6_Generic_Argument_Rejected\"><\/span>(6) Generic Argument Rejected<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The Court rejected the respondent\u2019s claim that \u201cOTRI\u201d was generic.<\/p>\n\n\n\n<p>The respondent failed to produce sufficient evidence of widespread use of the prefix in the pharmaceutical trade.<\/p>\n\n\n\n<p>Therefore, the Court held that the prefix retained distinctive association with OTRIVIN.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"judgment-delhi-high-court-gsk-vs-celebrity-biopharma\"><span class=\"ez-toc-section\" id=\"7_The_Judgment\"><\/span>7. The Judgment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Delhi High Court ultimately ruled in favour of GSK.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"key-findings-of-the-court\"><span class=\"ez-toc-section\" id=\"Key_Findings\"><\/span>Key Findings<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The Court held that:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>OTRINIR is deceptively similar to OTRIVIN<\/li>\n\n\n\n<li>The mark was registered in violation of Sections 9 and 11 of the Trade Marks Act<\/li>\n\n\n\n<li>The respondent\u2019s mark could not coexist with the earlier well-known brand.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"courts-directions\"><span class=\"ez-toc-section\" id=\"Courts_Directions\"><\/span>Court\u2019s Directions<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The Court ordered:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Cancellation of the trademark \u201cOTRINIR\u201d (Application No. 2892712)<\/li>\n\n\n\n<li>Removal of the mark from the Trademark Register<\/li>\n\n\n\n<li>The Trademark Registry to update its records accordingly.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"legal-principles-reinforced-by-the-judgment\"><span class=\"ez-toc-section\" id=\"8_Legal_Principles_Reinforced_by_the_Judgment\"><\/span>8. Legal Principles Reinforced by the Judgment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>This decision strengthens several important doctrines in trademark law.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"prior-user-prevails\"><span class=\"ez-toc-section\" id=\"1_Prior_User_Prevails\"><\/span>1. Prior User Prevails<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Indian trademark law gives greater importance to prior use than registration.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Even a registered mark can be cancelled if it conflicts with an earlier user.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"deceptive-similarity-test\"><span class=\"ez-toc-section\" id=\"2_Deceptive_Similarity_Test\"><\/span>2. Deceptive Similarity Test<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Courts assess similarity based on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Phonetic resemblance<\/li>\n\n\n\n<li>Visual appearance<\/li>\n\n\n\n<li>Structural composition<\/li>\n\n\n\n<li>Nature of goods<\/li>\n\n\n\n<li>Consumer perception<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"higher-standard-for-pharmaceutical-trademarks\"><span class=\"ez-toc-section\" id=\"3_Higher_Standard_for_Pharmaceutical_Trademarks\"><\/span>3. Higher Standard for Pharmaceutical Trademarks<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Courts apply stricter scrutiny in pharmaceutical cases.<\/p>\n\n\n\n<p>Even minor confusion between drug names can result in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Dispensing of the wrong medicine<\/li>\n\n\n\n<li>Potential health risks.<\/li>\n<\/ul>\n\n\n\n<p>This principle was strongly emphasized in the Supreme Court decision <em>Cadila Health Care v. Cadila Pharmaceuticals (2001)<\/em>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"prefix-dominance-rule\"><span class=\"ez-toc-section\" id=\"4_Prefix_Dominance_Rule\"><\/span>4. Prefix Dominance Rule<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Consumers often remember the beginning of a word mark.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Therefore, identical prefixes can create strong consumer association.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"public-interest-in-trademark-law\"><span class=\"ez-toc-section\" id=\"5_Public_Interest_in_Trademark_Law\"><\/span>5. Public Interest in Trademark Law<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Trademark disputes are not merely commercial conflicts.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In pharmaceutical cases, they involve public health considerations.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"practical-lessons-for-businesses-and-lawyers\"><span class=\"ez-toc-section\" id=\"9_Practical_Lessons_for_Businesses_and_Lawyers\"><\/span>9. Practical Lessons for Businesses and Lawyers<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The decision offers several practical insights.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"for-pharmaceutical-companies\"><span class=\"ez-toc-section\" id=\"For_Pharmaceutical_Companies\"><\/span>For Pharmaceutical Companies<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Conduct thorough trademark searches before adopting a brand name.<\/li>\n\n\n\n<li>Avoid names resembling well-known drug brands.<\/li>\n\n\n\n<li>Ensure brand names are distinctive and original.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"for-trademark-lawyers\"><span class=\"ez-toc-section\" id=\"For_Trademark_Lawyers\"><\/span>For Trademark Lawyers<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Gather extensive evidence of prior use, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Sales figures<\/li>\n\n\n\n<li>Advertising expenditure<\/li>\n\n\n\n<li>Market reputation<\/li>\n<\/ul>\n\n\n\n<p>Emphasize public health implications in pharmaceutical disputes.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"for-trademark-registry\"><span class=\"ez-toc-section\" id=\"For_Trademark_Registry\"><\/span>For Trademark Registry<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The judgment underscores the importance of careful examination during trademark registration, particularly in Class 5 pharmaceutical marks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"broader-impact-of-the-decision\"><span class=\"ez-toc-section\" id=\"10_Broader_Impact_of_the_Decision\"><\/span>10. Broader Impact of the Decision<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The ruling contributes to a growing body of Indian jurisprudence emphasizing strict protection for pharmaceutical trademarks.<\/p>\n\n\n\n<p>It signals that courts will not permit free-riding on established brands, particularly where such conduct may mislead consumers.<\/p>\n\n\n\n<p>The decision also reinforces the importance of distinctive brand creation in the pharmaceutical industry, encouraging companies to adopt inventive and unique names rather than derivative ones.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"conclusion-trademark-principles-reaffirmed\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Delhi High Court\u2019s decision in <em>GSK Consumer Healthcare S.A. v. Celebrity Biopharma Ltd. (2024)<\/em> is a significant reaffirmation of core trademark principles under Indian law.<\/p>\n\n\n\n<p>By cancelling the mark OTRINIR, the Court emphasized that:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Long-standing pharmaceutical brands deserve strong legal protection, and<\/li>\n\n\n\n<li>Consumer safety must remain paramount in trademark disputes involving medicines.<\/li>\n<\/ul>\n\n\n\n<p>Ultimately, the ruling reiterates a fundamental principle of trademark jurisprudence:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Where confusion in the pharmaceutical market is possible, the law must err on the side of caution.<\/p>\n<\/blockquote>\n\n\n\n<p>The judgment serves as a clear reminder that distinctiveness and diligence in brand selection are essential in the healthcare sector.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Take_Action_Protect_Your_Copyright_the_Right_Way\"><\/span>Take Action: Protect Your Copyright the Right Way<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Copyright registration may not be permanent or untouchable, but <strong>a properly prepared and legally sound registration can become a powerful shield for your intellectual property<\/strong>. The difference often lies in <strong>how the registration is filed, the documentation provided, and the legal strategy behind the application<\/strong>.<\/p>\n\n\n\n<p>Many copyright registrations face challenges later because of:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Incorrect ownership details<\/li>\n\n\n\n<li>Missing agreements or assignments<\/li>\n\n\n\n<li>Poor description of the work<\/li>\n\n\n\n<li>Lack of supporting documentation<\/li>\n\n\n\n<li>Applications filed without proper legal guidance<\/li>\n<\/ul>\n\n\n\n<p>Such mistakes can make even a registered copyright <strong>vulnerable to cancellation or rectification by the court<\/strong>.<\/p>\n\n\n\n<p>If you truly want your copyright to stand strong against legal challenges, it is essential that the registration is <strong>filed correctly from the very beginning<\/strong>.<\/p>\n\n\n\n<p><strong>Legal Service India.com<\/strong>, one of India\u2019s pioneering independent legal knowledge platforms founded in <strong>August 2000<\/strong>, provides <strong>professional copyright registration assistance through experienced intellectual property lawyers<\/strong>. Our team ensures that your copyright application is <strong>accurate, properly documented, and legally structured to withstand future disputes<\/strong>.<\/p>\n\n\n\n<p>Whether you are:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>An <strong>author or publisher<\/strong><\/li>\n\n\n\n<li>A <strong>software developer or startup<\/strong><\/li>\n\n\n\n<li>A <strong>designer or creative professional<\/strong><\/li>\n\n\n\n<li>A <strong>business protecting logos, content, or digital assets<\/strong><\/li>\n<\/ul>\n\n\n\n<p>we help ensure that your copyright registration is <strong>legally robust, defensible, and difficult to challenge<\/strong>.<\/p>\n\n\n\n<p>\ufe0f <strong>Do not leave your intellectual property vulnerable to disputes.<\/strong><\/p>\n\n\n\n<p><strong>Secure your copyright the right way with expert legal guidance.<\/strong><\/p>\n\n\n\n<p>\ud83d\udc49 <strong>Contact Legal Service India.com today for professional Copyright Registration assistance and make your copyright legally strong and dispute-resistant.<\/strong><\/p>\n\n\n\n<p>\ud83c\udf10 <strong>Website:<\/strong> <a target=\"_blank\" href=\"\/copyright\/register.htm\" rel=\"noreferrer noopener\">File Copyright Registration<\/a><br>\ud83d\udcf1 <strong>WhatsApp:<\/strong> +<a target=\"_blank\" href=\"https:\/\/wa.me\/919891244487\" rel=\"noreferrer noopener\">91 9891244487<\/a><\/p>\n\n\n\n<p><strong>Protect your creativity. Secure your rights. Strengthen your copyright.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gsk Consumer Healthcare S.A. vs. Celebrity Biopharma Ltd. &amp; Anr. (2024): A Landmark Decision on Pharmaceutical Trademark Similarity Particulars Details Court Delhi High Court Date Of Judgment 22 March 2024 Statute Trade Marks Act, 1999 \u2013 Sections 57, 9, and 11 Nature Of Case Trademark Rectification \/ Cancellation Introduction Trademark law performs a dual function.<\/p>\n","protected":false},"author":50,"featured_media":16828,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"two_page_speed":[],"_jetpack_memberships_contains_paid_content":false,"_joinchat":[],"footnotes":""},"categories":[21],"tags":[5149,28],"class_list":{"0":"post-16827","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-intellectual-property","8":"tag-intellectual-property","9":"tag-top-news"},"jetpack_featured_media_url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2026\/03\/gsk-consumer-healthcare-vs-celebrity-biopharma-trademark-case-delhi-high-court.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts\/16827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/users\/50"}],"replies":[{"embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/comments?post=16827"}],"version-history":[{"count":0,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts\/16827\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/media\/16828"}],"wp:attachment":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/media?parent=16827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/categories?post=16827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/tags?post=16827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}